Tadalafil Tablet, Film Coated
Product Images NDC 68071-3586

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 01)

Chemical structure diagram of tadalafil, showing its molecular framework including fused rings and functional groups consistent with the active ingredient tadalafil.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 02)

A set of four line graphs showing blood pressure changes over time in hours. The graphs display the difference in systolic and diastolic blood pressure between tadalafil and placebo groups, measured in standing and supine positions. Y-axes show pressure differences in mmHg; x-axes show time points from 0 to 96 hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 03)

Two line charts showing the effects of tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure over 24 hours post-dose. The upper chart depicts standing systolic blood pressure changes, and the lower chart shows supine systolic blood pressure changes.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 04)

A line graph depicting systolic blood pressure changes (in mmHg) over 12 hours after administration of tadalafil or placebo combined with doxazosin. The graph compares multiple groups including 20 mg tadalafil at 08:00 and 20:00, placebo with doxazosin, illustrating temporal blood pressure variations post-dosing.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 05)

A line graph showing plasma tadalafil concentration (µg/L) over time (hours) for three dosing conditions: single 20-mg dose, single 5-mg dose, and once-daily 5-mg dose after 5 consecutive days. Concentration peaks early and declines over 72 hours for single doses, with repeated dosing showing increased concentrations after 96 hours.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 06)

A line graph displaying the change from baseline in IPSS total score over a 12-week treatment period comparing tadalafil 5 mg and placebo. The x-axis shows duration of treatment in weeks, and the y-axis shows the change in score. Two lines represent tadalafil and placebo groups, with a noted statistical significance at p<0.01.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 07)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment period for tadalafil 5 mg tablets versus placebo. The x-axis represents treatment duration in weeks, while the y-axis shows the change in score. The graph indicates a greater reduction in IPSS score with tadalafil compared to placebo, with statistical significance noted at certain points.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 08)

A line graph displaying the least-squares mean change from baseline in weeks of therapy up to 26 weeks. The graph compares two groups: Tadalafil/Finasteride and Placebo/Finasteride, showing a greater decrease in the measured variable for the Tadalafil/Finasteride group over time. Statistical significance is indicated at several time points.*

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 09)

A line graph comparing the change from baseline in IPSS total score over a 12-week treatment duration for two groups: Tadalafil 5 mg and placebo. The graph shows a decreasing trend in IPSS score for both groups, with greater reduction for the Tadalafil 5 mg group.*

FDA Label Image

Unichem Logo (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 10)

FDA Label Image

Image (2c3d64d3 27b6 4ec1 Bd71 7c6bab4cd31d 11)

FDA Label Image

Pdp (68071 3586 9)

Label for tadalafil 5 mg tablets by NuCare Pharmaceuticals, Inc., showing NDC 68071-3586-9. The label states 90 tablets per package, describes the tablet as almond-shaped yellow film-coated with imprint '287' on one side and 'U' on the other. Manufactured by Unichem Laboratories Ltd., India. Includes storage instructions and warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.